Darolutamide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Darolutamide" in English language version.

refsWebsite
Global rank English rank
4th place
4th place
2nd place
2nd place
11th place
8th place
5th place
5th place
1st place
1st place
3rd place
3rd place
5,225th place
4,062nd place
3,984th place
2,622nd place
447th place
338th place
low place
low place
68th place
117th place
low place
low place
18th place
17th place
1,182nd place
725th place
low place
7,058th place
274th place
309th place
719th place
636th place

bath.ac.uk

researchportal.bath.ac.uk

books.google.com

cf.ac.uk

orca.cf.ac.uk

clinicaltrials.gov

doi.org

europa.eu

ema.europa.eu

ec.europa.eu

fda.gov

harvard.edu

ui.adsabs.harvard.edu

hres.ca

pdf.hres.ca

hpr-rps.hres.ca

medscape.com

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

chem.nlm.nih.gov

patents.google.com

semanticscholar.org

api.semanticscholar.org

springer.com

adisinsight.springer.com

tga.gov.au

  • "Nubeqa Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 4 March 2020. Retrieved 16 August 2020.
  • "AusPAR: Darolutamide". Therapeutic Goods Administration (TGA). 3 August 2020. Retrieved 22 September 2020.

web.archive.org

worldcat.org

search.worldcat.org

  • Gao X, Smith MR, Scher HI, Verholen F, Adorjan P, Dissanayake M, et al. (1 June 2023). "A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study". Journal of Clinical Oncology. 41 (16_suppl): TPS5111. doi:10.1200/JCO.2023.41.16_suppl.TPS5111. ISSN 0732-183X.
  • Laccetti AL, Smith MR, Scher HI, Verholen F, Adorjan P, Dissanayake M, et al. (1 February 2024). "ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)". Journal of Clinical Oncology. 42 (4_suppl): TPS243. doi:10.1200/JCO.2024.42.4_suppl.TPS243. ISSN 0732-183X.
  • Zurth C, Graudenz K, Denner K, Korjamo T, Fricke R, Wilkinson G, et al. (2019). "Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies". Journal of Clinical Oncology. 37 (7_suppl): 297. doi:10.1200/JCO.2019.37.7_suppl.297. ISSN 0732-183X. S2CID 87513637.
  • Tombal BF, Gillessen S, Loriot Y, Marreaud S, Collette L, Saad F (2018). "Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa)". Journal of Clinical Oncology. 36 (6_suppl): TPS406. doi:10.1200/JCO.2018.36.6_suppl.TPS406. ISSN 0732-183X.